Back to Newsroom
Back to Newsroom

APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm

Monday, 25 September 2017 04:01 PM

Khang & Khang LLP

Topic:

IRVINE, CA / ACCESSWIRE / September 25, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Depomed, Inc. ("Depomed" or the "Company") (NASDAQ: DEPO). Investors, who purchased or otherwise acquired Depomed shares from February 26, 2015 through August 7, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before October 17, 2017, the lead plaintiff motion deadline.

If you purchased Depomed shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, during the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On August 7, 2017, Depomed announced that it "recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids" and that Depomed had also received "subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice." When this news reached the public, Depomed's stock price dropped materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

SOURCE: Khang & Khang LLP

Topic:
Back to newsroom
Back to Newsroom
Share by: